Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

This study uses a blood test that detects tumor DNA (called ctDNA) to guide whether people who have had treatment for early-stage non-small cell lung cancer (NSCLC) need additional therapy. If ctDNA is detected after treatment, it may mean the cancer is still present, and the study will test whether adding immunotherapy helps. **You may be eligible if...** - You are 18 years old or older and have been diagnosed with NSCLC (stage IA2–IIIC) - You have completed all intended treatment (surgery and/or radiation, with or without chemotherapy) - No more than 32 weeks have passed since completing treatment - There is no currently detectable cancer on imaging - You have not received and are not planned to receive immunotherapy outside this study - Your blood counts and organ function are in acceptable range **You may NOT be eligible if...** - You have a specific EGFR, ALK, or ROS1 mutation (if adenocarcinoma subtype) - You have small cell lung cancer component - You have received immunotherapy before - You have known residual or recurrent disease after treatment Talk to your doctor to see if this trial is right for you.